Clinicopathologic factors affecting patient survival and tumor recurrence after orthotopic liver transplantation for hepatocellular carcinoma by Yokoyama, I et al.
l 
J 
. i 
• ! 
i 
l 
1 
! 
, 
I 
I 
.1 
-I! 
-I: 
: 
~ ! 
1 
i 
Clinicopathologic Factors Affecting Patient Survival and 
Tumor Recurrence After Orthotopic Liver Transplantation for 
Hepatocellular Carcinoma 
I. Yokoyama, D.G. Sheahan, B. Carr, S. Kakizoe, R. Selby, A.G. Tzakis, S. Todo, S. Iwatsuki, and 
T.E. Starzl 
THE role and value of orthotopic liver transplantation (OLTx) in the treatment of primary hepatic malignan-
cies have been debated because of high tumor recurrence 
rates.l-I Certain clinicopathologic entities have been 
shown to influence patient survival rates for hepatocellular 
carcinoma (HCC).3.4 In the current study, we analyzed 
various histopathologic features in the livers of 106 liver 
transplant recipients with HCC for their influence on 
patient outcome. 
PATIENTS METHODS 
During the period from January 1980 to December 1989. 106 (6%) 
of a total of 1.786 patients underwent OLTx because of the 
presence of HCC. They received cyc!osporine-steroid combina-
tion therapy for their basic immunosuppression. Chemotherapy 
was given to many of the pauents during the postoperative period, 
but the treatment was not based on a uniform protocol. 
The inftuence of the following risk factors was assessed: (I) 
tumor size, (2) tumor number. 131 shape of the tumor Icircum-
scribed or infiltrative), (4) tumor distribution within the liver juni-
or bilobar). (5) pseudocapsular formation. (6) vascular invasion. 
(7) liver capsule invasion, (8) tumor involvement at the resection 
margin, (9) lymph node metastasis. (10) hepatitis B. (J I) cirrhosis, 
and (12) fibrolamellar variant. 
The diagnosis of tumor recurrence was made using various 
radiologic imaging techniques. persistent elevation of serum ai-
pha-fetoprotem, exploratory surgery. or autopsy. The median 
follow-up penod was 30 months, with a range of 12 to 124 months. 
Data are shown as mean :!: SE. For pallent survival and 
disease-free penod. data analysis was pert'ormed by the method of 
Kaplan-Meier. A P value of less than 0.05 was considered to be 
significant. 
RESULTS 
The mean age of the 106 patients was 43.4 ± 1.8 years 
(range: 2 to 70 years). There were 71 males and 35 females. 
Sixty-five patients (61.3%) eventually died during the fol-
low-up period, 17 within 3 months of OLTx. The timing 
and cause of the deaths are summarized in Table 1. While 
noncancerous complications were responsible for all 
deaths within 3 months of OLTx except for that of 1 
patient. tumor recurrence was considered to be a direct 
cause of death in 36 of the 48 patients who survived more 
than 3 months after OLTx. In patients who died of causes 
other than their tumors, 4 were found to have recurrence 
of their tumor, which did not directly contribute to their 
death. 
In addition. 5 patients were alive with tumor recurrence 
at the time of last follow-up. Therefore. tumors recurred in 
Table 1. TIming and C8uu of o.th In 65 Patients Who Died 
After Ol Tx for HCC 
I ntraoperatlVe death 
Liver failure due to technical reason 
Liver failure other than technICal reason 
SystemiC sepsis 
Lymphoproliferative disorders 
Recurrent hepatrtlS 
Rejecbon 
Myocardial infarction 
AIDS 
Cancer 
Total 
'Inctuding 1 patient With COInadent recurrent cancer. 
tlncluding 2 patients WIth COII1Cldent recurrent cancer. 
<3mo 
2 
3 
5 
6" 
17 
;o3mo 
2 
6t 
1 
l' 
1 
36 
48 
a total of 45 patients or 51 % of the patients who survived 
more than 3 months. Eighty-five percent of the recur-
rences occurred within 12 months of OLTx. 
The survival rates of the 106 patients with HCC were 
65%, 39%, and 38% at 1, 3, and 5 years. respectively. after 
OLTx. On the other hand, the survival rates of 1.622 
patients who underwent OLTx for nonmalignant liver 
diseases were 73%. 69%. and 67% at 1. 3, and 5 years, 
respectively, after OLTx. The survival rates of the former 
were significantly lower than those of the latter (p < .001) 
(fig I). 
The tumors of II of 106 patients (10.4%) had fibrola-
meHar variant HCC CFL-HCC). The overall disease-free 
period of patients with FL·HCC was similar to that of 
patients with non-FL-HCC. However, in the patients with 
tumors of 5 cm or greater, the disease-free period of 
patients with FL-HCC was significantly longer than that of 
patients with non-FL-HCC (P < .05) (Fig 2). The influence 
of each factor on the incidence of tumor recurrence in 9 
patients with FL-HCC who survived 3 months is examined 
in Table 2. 
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Fig 1. Patient sUMVal rates after OlTx for HCC (n = 106) and for 
nonmahgnancy (n = 1.622) (P < .05). 
The influence of the above mentioned 12 clinicopatho-
logic factors on the disease·free period was studied in the 
patients with non-FL·HCC (Table 3. univariate analysis/. 
Sixteen patients with non-FL·HCC who died without 
recurrence within 3 months postoperatively were ex· 
cluded. leaving 80 patients for the analysis. The favorable 
factors for disease·free period were tumor size of less than 
5 cm in diameter. single tumor. no vascular invasion. no 
lymph node metastasis. presence of pseudocapsule. cir· 
cumscribed tumor. absence of margin invasion. and unilo-
bar involvement. Among all of the factors. absence of 
vascular invasion was associated with the lowest rate of 
recurrence iP < .0001), 
Multivariate analysis of these factors revealed that tu· 
mors with gross vascular invasion were associated with an 
incidence of recurrence 42 times higher than that of tumors 
without such invasion. Other factors that independently 
affected tumor recurrence in order of decreasing frequency 
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Fig 2. Disease-free survival rates for patients with FL·HCC (n = 
9) and patients With non·FL·HCC (n = 46) who sUMVed more than 
3 months after receiving their transplant. Tumors less than 5 em in 
diameter were excluded (P < .05). 
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Table 2. Incldenc:e of Recunence Within 3 Yea ... After Uver Tx 
In 8 Patients with FL-HCC (3-Month Survivors) 
No. Patients 
Tumor Character No.' w,th Recurrence 
Tumor sIZe 
<5cm 1 0 
2:Scm 8 4 
Tumor number 
Single 2 a 
Multiple 7 4 
Vascular invaslOl1 
(-) 3 0 
Microsalpic 1 1 
MacroscoPIC 5 3 
Pseudocapsule 
(-) 8 3 
(+) 0 0 
Lymph node 
(-) 7 3 
(+) 2 
Tumor shape 
Circumscnbed 6 2 
Infiltrative 2 
Capsular invasion 
(-) 8 4 
(+) 0 
Margin 
(-) 9 4 
(+) 0 0 
Hepatitis B 
(-) 9 4 
(+) 0 0 
CirrhosiS 
(-) 8 4 
(+) 0 
Involvement ot lobes 
Unilobe 1 0 
Bilobe B 4 
·Data not available for some pattents. 
were microvascular invasion. non·FL·HCC. bilobar distri· 
bution. and absence of pseudocapsular formation (Table 
4). 
When the tumors were classified by their TNM stage. 
the survival rates of patients with tumors in stages I (n = 
3) and II (n = 19) were significantly better than those of 
patients with tumors in stages III (n = 23) and IV (n = 50) 
(Fig 3). 
DISCUSSION 
Tumor recurrence is a major cause of patient death after 
OLTx for HCC. In the present study. the rate of recur· 
rence was found to be well correlated with certain distinc· 
tive pathologic features. 
In this analysis. the most statistically sigmficam adverse 
prognostic factor was macroscopic vascular invasion by 
tumor. Other adverse prognostic factors of significance 
included tumor size 5 cm in diameter or greater. multifo-
cality of the tumor. infiltrating type (in contrast to nodular. 
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Tible 3. Cllnlc:opd1ologlc Fac:tora Ina 01 ..... FnIe Period In 
Pllllenta with Non-fL·HCC (3-Month SurvivorS) 
a~f%F 
FacIDr No. 1 y 3y Sy PValue 
Tumor sIZe 
<Scm 34 75.4 71.4 71.4 p< .001 
1 ~Rcm 46 41.3 29.1 29.1 
I Tumor number ., 
I, Single 23 82.6 78.0 78.0 p< .005 ~ ~ , Mu. 57 46.0 33.3 33.3 
i Vascular invasion 
1 
(-) 22 95.2 95.2 95.2 p< .0001 
Microscopic 30 70.0 49.8 49.8 
MacroscopIC 28 11.9 0.0 
PS!M Idocapsule I (-) 63 51.1 37.0 37.0 P< .01 (+) 17 81.6 81.6 81.6 Lymph node (-) 76 59.8 49.2 49.2 P= .09 jl (+) 4 0.0 
\.! 
Tumor shape 
Circumscnbed 55" 70.0 63.2 63.2 P<001 
.: Infiltrative 24 25.1 0.0 
.' Capsular invasion , 
'1: H 72 57.5 47.2 47.2 P= .1 I j, (+) 8 43.8 43.8 43.8 
i. Margin !. 
:1 
(-) 74 74.3 55.9 52.2 P< .05 
(+) 6 33.3 0.0 
Hepatitis B 
(-) 60 60.6 50.4 50.4 P= .3 
(+) 20 42.7 36.6 36.6 
Cirrhosis 
(-) 59 59.3 52.2 52.2 P= .2 
(+) 21 48.0 33.6 33.6 
InYOivement of lobes 
Unilobe 44 81.6 67.6 67.6 P< .0001 
Bilobe 36 28.5 28.5 28.5 
• Data not 8V8I1ab1e for' patient. 
circumscribed type) of tumor. and bilobar involvement. 
Although the frequency of lymph node involvement by 
tumor or positive resection margin is relatively small (less 
than 5%). patients with these adverse factors were invari· 
ably found to have early tumor recurrence. 
qKbfe~K R......,. RIIIk of Tumor Recurrence by 
Mulllvlrta Analystl 
Factor ReIaIMt RiSk 
Gross vascular InvasIOn 42 
Microscopic vasaJlar ilWlSion 18 
Non-FL·HCC 16 
Bilobar distributiOn 6 
Pseudocapsular formation 4 
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Fig 3. Companson of patient sUrvIVal rates among TNM stage I 
and II (n = 22). III (n = 23), and IV (n = 50) tumors for patients with 
non-FL-HCC. The differences were significant among the groups 
(P< .01). 
Factors that were significantly associated with a better 
prognosis included tumor size less than 5 cm in diameter 
and pseudocapsular formation. Fibrolamellar variant was 
also a favorable factor that independently affected the 
prognosis. This subtype tumor of HCC. which often pres-
ents in transplant candidates when the disease is at an 
advanced stage. is characterized by its less invasive and 
slow·growing nature. ~ 
Survival of patients with non-FL-HCC was inversely 
related to TNM stage. The survival of patients with stage 
I and II tumors far exceeded that of other groups (stages 
III and IV). A similar observation was reported by the 
Hanover group. J There were no long-term survivors seen 
in patients with stage IV tumors. For this poor prognostic 
group. adjuvant anticancer therapy may prolong the tu-
mor·free survival rate. Recently. we started to investigate 
systemically the value of adjuvant therapy before and after 
transplantation for patients with hepatic malignancy. 
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